Securities code: Beijing Scitop Bio-Tech Co.Ltd(300858) securities abbreviation: Beijing Scitop Bio-Tech Co.Ltd(300858) Announcement No.: 2022038 Beijing Scitop Bio-Tech Co.Ltd(300858)
Regulatory measures taken by securities regulatory authorities and exchanges in the past five years
Or announcement of punishment and rectification
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Beijing Scitop Bio-Tech Co.Ltd(300858) (hereinafter referred to as “the company”) has been committed to improving the corporate governance structure, establishing and improving the internal control system, standardizing the company’s operation and promoting the sustainable, stable and healthy development of the company in strict accordance with the company law of the people’s Republic of China, the Securities Law of the people’s Republic of China, the Listing Rules of Shenzhen Stock Exchange on the gem and other relevant laws and regulations and the articles of association since its listing, Continuously improve the level of corporate governance.
In view of the company’s intention to issue shares to specific objects, according to relevant requirements, the company’s regulatory measures or punishment and rectification taken by the securities regulatory authority and the exchange in the past five years are hereby announced as follows: I. The company’s punishment by the securities regulatory authority and the exchange in the past five years
In the last five years, the company has not been punished by the securities regulatory authority or the exchange. 2、 Regulatory measures taken by securities regulatory authorities and exchanges and their rectification in the past five years
In the last five years, the company has been taken regulatory measures by the securities regulatory department and the exchange once.
1. Existing problems
On June 30, 2020, the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) issued the decision on the regulatory measures of issuing warning letters to Beijing Scitop Bio-Tech Co.Ltd(300858) the people’s Republic of China (hereinafter referred to as the “warning letters”). The details are as follows:
After investigation, the CSRC found that the company had the following problems in the process of applying for the initial public offering of shares on the gem: the company and Mengniu Dairy agreed in the purchase and sales contract signed in December 2019 that the price of the main products sold to Mengniu Dairy would be adjusted from 3% to 6% in 2020, but in the documents submitted by the company before the issuance and examination meeting, The change of the above price reduction range from 3% to 6% and its impact on the company’s sustainable operation were not disclosed, and it was not explained when answering the question about the pricing mechanism of the company’s transaction with Mengniu Dairy at the hearing session of the development and examination committee.
The above-mentioned acts violate the relevant provisions of Article 4 of the measures for the administration of initial public offering and listing on the gem applicable when the issuance and Examination Commission is held on May 14, 2020, and constitute the acts described in Article 54 of the measures for the administration of initial public offering and listing on the gem. In accordance with Article 54 of the measures for the administration of initial public offering and listing on the gem, the CSRC has decided to take administrative supervision measures to issue warning letters to the company.
2. Rectification
After receiving the above warning letter, the company has made full risk disclosure on the matters involved in the warning letter in the letter of intent for offering publicly disclosed on July 7, 2020 and the prospectus disclosed on July 14, 2020, and analyzed in detail the impact of relevant matters on the company’s operating performance, so as to ensure the authenticity of the information disclosure documents when the company makes an initial public offering of shares and is listed on the gem Accuracy, completeness and timeliness.
Since its listing, the company has attached great importance to compliance operation and information disclosure, and continuously strengthened the study of directors, supervisors, senior managers and relevant personnel on relevant laws, regulations and normative documents such as the securities law of the people’s Republic of China, the measures for the administration of information disclosure of listed companies, the stock listing rules of Shenzhen Stock Exchange, so as to further improve the awareness of standardized operation. At the same time, the company strengthened internal control and management, practically improved the quality of information disclosure, timely fulfilled the obligation of information disclosure in strict accordance with the relevant requirements and regulations of China Securities Regulatory Commission and Shenzhen Stock Exchange, ensured the authenticity, accuracy and integrity of information disclosure, and better safeguarded the legitimate rights and interests of all shareholders of the company.
In addition to the above, the company has not been subject to other regulatory measures taken by the securities regulatory authorities or exchanges in the past five years.
It is hereby announced.
Beijing Scitop Bio-Tech Co.Ltd(300858) board of directors April 26, 2022
